半导体激光透巩膜睫状体光凝治疗新生血管性青光眼

Transscleral diode laser cyclophotocoagulation for the treatment of neovascular glaucoma

目的 评价利用半导体激光透巩膜睫状体光凝治疗新生血管性青光眼的效果。方法 对 4 2例药物控制不良的新生血管性青光眼患眼进行 810nm半导体激光的透巩膜睫状体光凝 ,能量为 1.5 0～ 2 .2 5W ,时间为 2s,范围 180°～ 2 70° ,观察 6个月的治疗效果。结果 治疗前眼压为 ( 4 5 .3± 3.7)mmHg( 35～ 5 6mmHg ,1kPa =7.5mmHg) ,经过第 1次治疗后的眼压是 ( 18.2± 2 .1)mmHg( 12～ 33mmHg) ,随访最后统计的眼压是 ( 17.6± 1.6 )mmHg( 13～ 2 9mmHg) ,术后眼压明显低于术前 (P <0 .0 5 )。在随访结束时 ,33眼 ( 78.6 % )治疗取得成功。结论 透巩膜半导体激光睫状体光凝是治疗新生血管性青光眼的一种有效的方法 ,而且操作方便 。

Objective To evaluate the outcome of contact transscleral diode laser cyclophotocoagulation (CTDC) for eyes with neovascular glaucoma.Methods There in the study were 42 eyes with neovascular glaucoma,they were received treatments with energy of 1.50～2.25 W applied for 2 seconds, 180°～270°.The patients were followed at least six months.Results The mean pretreatment intraocular pressure (IOP) was 45.3 mmHg±3.7mmHg(35～56mmHg,1kPa=7 5mmHg),after first treatment,there was significant decrease in IOP and the mean IOP was 18 2mmHg±2 1mmHg(12～33mmHg)( P <0.05),and 17.6 mmHg±1 6mmHg(13～29mmHg)( P <0.05)at last follow up.The success rate was 78.6%(33 of 42).Conclusion CTDC is a safe and effective therapy means in eyes with advanced neovascular glaucoma.